January 21, 2011 — The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee decided that it could not recommend approval of Amyvid (florbetapir) at this time based on the currently available data (13-3); but, voted unanimously (16-0) to recommend approval of Amyvid conditional on a reader training program that demonstrates reader accuracy and consistency through a re-read of previously acquired scans. The committee said efficacy was established and there were no significant safety concerns raised.

Amyvid is an imaging tool indicated for positron emission tomography (PET) imaging of beta-amyloid plaque in the brain. It is being investigated for the potential use in ruling out Alzheimer's disease. In addition to the pivotal phase III "Image-to-Autopsy" study, other clinical studies are also being conducted in the European Union., North and South America, Australia and Asia. The committee stated that a negative scan would be clinically useful in indicating that Alzheimer's pathology is unlikely to be the cause of a patient's cognitive decline.

Lilly acquired Avid Radiopharmaceuticals Inc. in December 2010. Amyvid is Avid's lead candidate and was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the United States. Amyvid was recently assigned priority review designation by the FDA.

The FDA will consider the panel's recommendation in its review of Amyvid. The FDA takes the advice of its advisory committees into consideration when reviewing investigational drugs, but is not bound by their recommendations.

For more information: www.lilly.com

Related Content

News | Ultrasound Imaging

May 24, 2022 — Mindray, a global leader and developer of healthcare technologies and solutions for ultrasound, patient ...

Time May 24, 2022
arrow
News | Radiology Business

May 23, 2022 — AHRA, The Association for Medical Imaging Management, the professional organization representing all ...

Time May 23, 2022
arrow
News | Coronavirus (COVID-19)

May 23, 2022 — The clinical and imaging characteristics of COVID-19 breakthrough infections in fully vaccinated patients ...

Time May 23, 2022
arrow
News | Lung Imaging

May 23, 2022 — Xoran Technologies announced they have completed Phase 1 for their NHLBI grant for mobile lung CT. Just ...

Time May 23, 2022
arrow
News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
Feature | Coronavirus (COVID-19)

Clinical scientists used machine learning (ML) models to explore de-identified electronic health record (EHR) data in ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Imaging Technology News (ITN) won the National Gold Award for its PHOTO GALLERY: How COVID-19 Appears on Medical Imaging ...

Time May 13, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
Subscribe Now